Partnership integrates ClearStrand-ASD with full-spectrum care to streamline autism diagnosis and early intervention
LinusBio, a company that leads in precision exposome medicine, and Coralis Health, a virtual care platform that helps neurodivergent children and their families, have joined forces. Their partnership offers a full range of diagnostic services for autism spectrum disorder (ASD). This new collaboration combines LinusBio’s ClearStrand-ASD test, which detects specific biomarkers, with Coralis Health’s care platform. Together, they create a smooth path from early screening to diagnosis and treatment.
Health Technology Insights: ELLKAY CEO Joins White House Summit on Health IT Interoperability
“This partnership shows the kind of innovation we need to change how autism care is provided,” said Dr. Manish Arora, the founder and CEO of LinusBio. This partnership helps fill a big gap in diagnosing and treating autism. It connects families who get ClearStrand-ASD results that suggest a possible autism risk to Coralis Health’s network of experts. This greatly speeds up the usual long waiting time for diagnosis, bringing it down to just 90 days. Once the results are ready, LinusBio sends qualifying families to Coralis Health. Within five days, virtual care teams contact the families to set up appointments and complete full evaluations within 90 days.
This service is mainly for families who are worried about their child’s development and are looking for both screening insights and professional diagnostic help. Healthcare providers can also use this streamlined path to offer their patients a full diagnostic solution that makes it easier to refer and reduces wait times for autism evaluations.
Health Technology Insights: Rainfall Health Applauds CMS Outcome-Based Care Launch
Making the path to diagnosis easier is critical because studies show early diagnosis and treatment lead to better outcomes. However, many families still face long waits for diagnostic help. Families worried about autism often wait years for evaluations, delaying important early treatments. This partnership creates a direct link between biomarker screening and virtual diagnostic services, cutting the time from when there’s concern to when a professional evaluation happens.
Dr. Arora added, “ClearStrand-ASD gives families important early information, but we know many families need support with the next steps. Partnering with Coralis Health allows us to offer a full solution that takes families from screening all the way through diagnosis and into treatment — all through one coordinated path.” Dr. Ayesha Cheema-Hasan, founder and CEO of Coralis Health, said, “Our goal has always been to connect children to life-changing therapies as quickly as possible, while giving them the best care. We also want to help clinicians by finding ways to standardize care in a field that’s too reliant on individual expertise and training. Using technology wisely, we aim to close the gap in access and make sure every child has the chance to thrive no matter where they start.”
Health Technology Insights: Avanos Announces Divestiture of Hyaluronic Acid Product Line to Channel-Markers Medical
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
